+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review

Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. Lexicon is focusing on the introduction of its approved medication, Inpefa (sotagliflozin), into the market specifically for the treatment of heart failure. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for hypertrophic cardiomyopathy (HCM) and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.

Lexicon Pharmaceuticals Inc Key Recent Developments

  • May 03, 2024: Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
  • Apr 29, 2024: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
  • Apr 29, 2024: Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
  • Apr 18, 2024: Lexicon Pharmaceuticals to Host 2024 Investor Day

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Lexicon Pharmaceuticals Inc - Key Facts
  • Lexicon Pharmaceuticals Inc - Key Employees
  • Lexicon Pharmaceuticals Inc - Key Employee Biographies
  • Lexicon Pharmaceuticals Inc - Major Products and Services
  • Lexicon Pharmaceuticals Inc - History
  • Lexicon Pharmaceuticals Inc - Company Statement
  • Lexicon Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Lexicon Pharmaceuticals Inc - Business Description
  • R&D Overview
  • Lexicon Pharmaceuticals Inc - Corporate Strategy
  • Lexicon Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Lexicon Pharmaceuticals Inc - Strengths
  • Lexicon Pharmaceuticals Inc - Weaknesses
  • Lexicon Pharmaceuticals Inc - Opportunities
  • Lexicon Pharmaceuticals Inc - Threats
  • Lexicon Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Lexicon Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 03, 2024: Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
  • Apr 29, 2024: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
  • Apr 29, 2024: Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
  • Apr 18, 2024: Lexicon Pharmaceuticals to Host 2024 Investor Day
  • Mar 11, 2024: Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
  • Jan 08, 2024: Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
  • Nov 08, 2023: Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
  • Oct 31, 2023: Lexicon Strengthens Management Team With Two New Executives
  • Oct 09, 2023: Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
  • Jul 28, 2023: Lexicon Elects Diane E. Sullivan to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Lexicon Pharmaceuticals Inc, Key Facts
  • Lexicon Pharmaceuticals Inc, Key Employees
  • Lexicon Pharmaceuticals Inc, Key Employee Biographies
  • Lexicon Pharmaceuticals Inc, Major Products and Services
  • Lexicon Pharmaceuticals Inc, History
  • Lexicon Pharmaceuticals Inc, Subsidiaries
  • Lexicon Pharmaceuticals Inc, Key Competitors
  • Lexicon Pharmaceuticals Inc, Ratios based on current share price
  • Lexicon Pharmaceuticals Inc, Annual Ratios
  • Lexicon Pharmaceuticals Inc, Interim Ratios
  • Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Lexicon Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Lexicon Pharmaceuticals Inc, Performance Chart (2019 - 2023)
  • Lexicon Pharmaceuticals Inc, Ratio Charts
  • Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acorda Therapeutics Inc
  • Eli Lilly and Co
  • Boehringer Ingelheim International GmbH
  • RepliCel Life Sciences Inc
  • Geron Corp
  • AstraZeneca Plc
  • Janssen Pharmaceuticals Inc